Brexpiprazol (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Brexpiprazol" in Spanish language version.

refsWebsite

Global rank Spanish rank

9doi.org

2^nd place

8nih.gov

4^th place

6clinicaltrials.gov

5,225^th place

9,066^th place

2fda.gov

447^th place

668^th place

1accessmylibrary.com

1,935^th place

2,019^th place

1anvisa.gov.br

low place

1gov.br

5,564^th place

6,863^rd place

1empr.com

low place

1news-medical.net

8,069^th place

5,235^th place

1unc.edu

1,538^th place

1,360^th place

1uam.es

7,583^rd place

845^th place

1derangedphysiology.com

low place

1healio.com

low place

1otsuka.co.jp

low place

1web.archive.org

1^st place

1lundbeck.com

low place

1springer.com

274^th place

245^th place

1archive.org

6^th place

5^th place

accessmylibrary.com

«Otsuka HD places top priority on development of OPC-34712.». Chemical Business Newsbase. 3 de enero de 2011. Consultado el 10 de febrero de 2012.

anvisa.gov.br

antigo.anvisa.gov.br

«Rexulti (Brexpiprazole): novo registro». Č Informações Técnicas - Anvisa. Consultado el 25 de septiembre de 2022.

archive.org

Howland RH (April 2015). «Brexpiprazole: another multipurpose antipsychotic drug?». Journal of Psychosocial Nursing and Mental Health Services 53 (4): 23-25. PMID 25856810. doi:10.3928/02793695-20150323-01.

clinicaltrials.gov

«OPC-34712 search results». Consultado el 10 de febrero de 2012.
Otsuka Pharmaceutical Development & Commercialization, Inc. (30 de noviembre de 2015). A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPDC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Polaris Trial (NCT01360632). clinicaltrials.gov. Consultado el 2 de mayo de 2023.
Otsuka Pharmaceutical Development & Commercialization, Inc. (29 de septiembre de 2015). A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder (NCT01423916). clinicaltrials.gov. Consultado el 2 de mayo de 2023.
Otsuka Pharmaceutical Development & Commercialization, Inc. (29 de septiembre de 2015). A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (NCT01396421). clinicaltrials.gov. Consultado el 2 de mayo de 2023.
«A Long-term Trial of OPC-34712 in Patients With Schizophrenia - Full Text View - ClinicalTrials.gov». clinicaltrials.gov (en inglés). Consultado el 3 de mayo de 2023.
Otsuka Pharmaceutical Development & Commercialization, Inc. (6 de enero de 2023). A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/ Hyperactivity Disorder (NCT01074294). clinicaltrials.gov. Consultado el 2 de mayo de 2023.

derangedphysiology.com

«Full agonists, partial agonists and inverse agonists | Deranged Physiology».

doi.org

dx.doi.org

Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (June 2021). «Discovery research and development history of the dopamine D₂ receptor partial agonists, aripiprazole and brexpiprazole». Neuropsychopharmacology Reports 41 (2): 134-143. PMC 8340839. PMID 33960741. doi:10.1002/npr2.12180.
Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, Poluzzi E (September 2022). «Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System». The International Journal of Neuropsychopharmacology 25 (9): 727-736. PMC 9515127. PMID 35639870. doi:10.1093/ijnp/pyac031.
Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T (September 2014). «Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator». The Journal of Pharmacology and Experimental Therapeutics 350 (3): 589-604. PMID 24947465. doi:10.1124/jpet.114.213793.
Das S, Barnwal P, Winston AB, Mondal S, Saha I (February 2016). «Brexpiprazole: so far so good». Therapeutic Advances in Psychopharmacology 6 (1): 39-54. PMC 4749739. PMID 26913177. doi:10.1177/2045125315614739.
Clarke WP, Bond RA (July 1998). «The elusive nature of intrinsic efficacy». Trends in Pharmacological Sciences 19 (7): 270-276. PMID 9703760. doi:10.1016/s0165-6147(97)01138-3.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (August 2002). «Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride». Neuropsychopharmacology 27 (2): 248-259. PMID 12093598. doi:10.1016/S0893-133X(02)00304-4.
«Intrinsic Efficacy». Encyclopedia of Molecular Pharmacology. 2008. p. 652. ISBN 978-3-540-38916-3. doi:10.1007/978-3-540-38918-7_6001.
Stahl SM (February 2016). «Mechanism of action of brexpiprazole: comparison with aripiprazole». CNS Spectrums 21 (1): 1-6. PMID 26899451. doi:10.1017/S1092852915000954.
Howland RH (April 2015). «Brexpiprazole: another multipurpose antipsychotic drug?». Journal of Psychosocial Nursing and Mental Health Services 53 (4): 23-25. PMID 25856810. doi:10.3928/02793695-20150323-01.

empr.com

«Rexulti Approval Expanded to Include Adolescents With Schizophrenia». MPR. 29 de diciembre de 2021. Consultado el 25 de septiembre de 2022.

fda.gov

accessdata.fda.gov

«Rexulti (brexpiprazole) Tablets». U.S. Food and Drug Administration (FDA). 10 de julio de 2015. Consultado el 18 de agosto de 2020.

fda.gov

«2022 First Generic Drug Approvals». U.S. Food and Drug Administration (FDA). 3 de marzo de 2023. Consultado el 30 de abril de 2023.

gov.br

«Rexulti (Brexpiprazole): novo registro». Agência Nacional de Vigilância Sanitária - Anvisa (en portugués de Brasil). Consultado el 25 de septiembre de 2022.

healio.com

«Otsuka, Lundbeck initiate phase 3 trials of Rexulti for bipolar I disorder». www.healio.com. Consultado el 16 de octubre de 2017.

lundbeck.com

investor.lundbeck.com

«Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide». Lundbeck. Archivado desde el original el 1 de abril de 2012. Consultado el 10 de febrero de 2012.

news-medical.net

«Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder». News-Medical.Net. 16 de mayo de 2011. Consultado el 10 de febrero de 2012.

nih.gov

ncbi.nlm.nih.gov

Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (June 2021). «Discovery research and development history of the dopamine D₂ receptor partial agonists, aripiprazole and brexpiprazole». Neuropsychopharmacology Reports 41 (2): 134-143. PMC 8340839. PMID 33960741. doi:10.1002/npr2.12180.
Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, Poluzzi E (September 2022). «Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System». The International Journal of Neuropsychopharmacology 25 (9): 727-736. PMC 9515127. PMID 35639870. doi:10.1093/ijnp/pyac031.
Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T (September 2014). «Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator». The Journal of Pharmacology and Experimental Therapeutics 350 (3): 589-604. PMID 24947465. doi:10.1124/jpet.114.213793.
Das S, Barnwal P, Winston AB, Mondal S, Saha I (February 2016). «Brexpiprazole: so far so good». Therapeutic Advances in Psychopharmacology 6 (1): 39-54. PMC 4749739. PMID 26913177. doi:10.1177/2045125315614739.
Clarke WP, Bond RA (July 1998). «The elusive nature of intrinsic efficacy». Trends in Pharmacological Sciences 19 (7): 270-276. PMID 9703760. doi:10.1016/s0165-6147(97)01138-3.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (August 2002). «Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride». Neuropsychopharmacology 27 (2): 248-259. PMID 12093598. doi:10.1016/S0893-133X(02)00304-4.
Stahl SM (February 2016). «Mechanism of action of brexpiprazole: comparison with aripiprazole». CNS Spectrums 21 (1): 1-6. PMID 26899451. doi:10.1017/S1092852915000954.
Howland RH (April 2015). «Brexpiprazole: another multipurpose antipsychotic drug?». Journal of Psychosocial Nursing and Mental Health Services 53 (4): 23-25. PMID 25856810. doi:10.3928/02793695-20150323-01.

otsuka.co.jp

«Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia｜News Releases». Otsuka Pharmaceutical Co., Ltd. Consultado el 4 de octubre de 2018.

springer.com

adisinsight.springer.com

«Brexpiprazole - Lundbeck/Otsuka». AdisInsight. Springer Nature Switzerland AG.

uam.es

pdg.cnb.uam.es

«Glaxo Wellcome pharmacology guide».

unc.edu

pdsp.unc.edu

«PDSP K_i Database». Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Consultado el 14 de agosto de 2017.

web.archive.org

«Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide». Lundbeck. Archivado desde el original el 1 de abril de 2012. Consultado el 10 de febrero de 2012.